Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
Published 2012 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Increasing Serum Half-life and Extending Cholesterol Loweringin Vivoby Engineering Antibody with pH-sensitive Binding to PCSK9
Authors
Keywords
-
Journal
JOURNAL OF BIOLOGICAL CHEMISTRY
Volume 287, Issue 14, Pages 11090-11097
Publisher
American Society for Biochemistry & Molecular Biology (ASBMB)
Online
2012-02-01
DOI
10.1074/jbc.m111.319764
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- A combinatorial histidine scanning library approach to engineer highly pH-dependent protein switches
- (2011) Megan L. Murtaugh et al. PROTEIN SCIENCE
- Population Pharmacokinetics of Therapeutic Monoclonal Antibodies
- (2010) Nathanael L. Dirks et al. CLINICAL PHARMACOKINETICS
- Strategies for proprotein convertase subtilisin kexin 9 modulation: a perspective on recent patents
- (2010) Marianne Abifadel et al. EXPERT OPINION ON THERAPEUTIC PATENTS
- A Proprotein Convertase Subtilisin-like/Kexin Type 9 (PCSK9) C-terminal Domain Antibody Antigen-binding Fragment Inhibits PCSK9 Internalization and Restores Low Density Lipoprotein Uptake
- (2010) Yan G. Ni et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- A PCSK9-binding antibody that structurally mimics the EGF(A) domain of LDL-receptor reduces LDL cholesterol in vivo
- (2010) Yan G. Ni et al. JOURNAL OF LIPID RESEARCH
- Antibody recycling by engineered pH-dependent antigen binding improves the duration of antigen neutralization
- (2010) Tomoyuki Igawa et al. NATURE BIOTECHNOLOGY
- Enhanced antibody half-life improves in vivo activity
- (2010) Jonathan Zalevsky et al. NATURE BIOTECHNOLOGY
- Development trends for human monoclonal antibody therapeutics
- (2010) Aaron L. Nelson et al. NATURE REVIEWS DRUG DISCOVERY
- Biodistribution Mechanisms of Therapeutic Monoclonal Antibodies in Health and Disease
- (2009) Mohammad Tabrizi et al. AAPS Journal
- Engineering Human IgG1 Affinity to Human Neonatal Fc Receptor: Impact of Affinity Improvement on Pharmacokinetics in Primates
- (2009) Y. A. Yeung et al. JOURNAL OF IMMUNOLOGY
- A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates
- (2009) J. C. Y. Chan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Molecular basis of PCSK9 function
- (2008) Gilles Lambert et al. ATHEROSCLEROSIS
- Monoclonal Antibody Pharmacokinetics and Pharmacodynamics
- (2008) W Wang et al. CLINICAL PHARMACOLOGY & THERAPEUTICS
- Structural and Biochemical Characterization of the Wild Type PCSK9-EGF(AB) Complex and Natural Familial Hypercholesterolemia Mutants
- (2008) Matthew J. Bottomley et al. JOURNAL OF BIOLOGICAL CHEMISTRY
- PCSK9: a convertase that coordinates LDL catabolism
- (2008) Jay D. Horton et al. JOURNAL OF LIPID RESEARCH
- Structural requirements for PCSK9-mediated degradation of the low-density lipoprotein receptor
- (2008) D.-W. Zhang et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started